-

Shareholder Alert: Robbins LLP Announces It Is Investigating Hallmark Financial Services Inc. (HALL) for Misleading Shareholders

SAN DIEGO & DALLAS--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that it is investigating Hallmark Financial Services Inc. (NASDAQ: HALL) for alleged violations of the Securities Exchange Act of 1934 and whether the Company's officers and directors breached their fiduciary duties to shareholders. Hallmark Financial underwrites, markets, distributes, and services property/casualty insurance products.

If you suffered a loss as a result of Hallmark Financial's misconduct, click here.

Hallmark Financial Services Inc. (HALL) Dismisses Its Independent Auditor

On March 2, 2020, Hallmark Financial announced that it had exited from the Binding Primary Commercial Auto Business and revealed a $63.8 million loss development for prior underwriting years. Then, on March 11, 2020, the Company disclosed it had dismissed its independent auditor BDO due in large part to a disagreement regarding estimates for reserves on unpaid losses. Finally, on March 17, 2020, Hallmark Financial filed with the SEC a letter from BDO stating BDO had expanded the scope of its audit relating to the disagreement and that "a substantial portion of the requests had not been received and/or tested prior to our termination." Following these disclosures, shares of Hallmark Financial fell from a closing price of $14.33 per share on March 2, 2020 to a closing price of $3.12 per share on March 18, 2020, representing a 78% decline.

If you purchased Hallmark Financial Services Inc. (HALL) securities between March 5, 2019 and March 17, 2020, you have until July 6, 2020, to ask the court to be appointed lead plaintiff for the class.

Contact us to learn more:
Leo Kandinov
(800) 350-6003
lkandinov@robbinsllp.com
Shareholder Information Form

Want to be notified if a class action against Hallmark Financial settles? Want to receive free alerts about companies engaged in wrongdoing? Sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

Robbins LLP

NASDAQ:HALL

Release Versions
$Cashtags

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Snowflake Inc. Class Action Reminder - Robbins LLP Encourages SNOW Stockholders to Contact the Firm for Information About Their Rights

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Snowflake Inc. (NYSE: SNOW) Class A common stock between June 27, 2023 and February 28, 2024. Snowflake is a software company that provides cloud data storage that enables customers to consolidate data onto data-driven applications and share data for the purpose of running analytics and other processes. For more information, submit a form, ema...

Corcept Therapeutics Incorporated Class Action Reminder – Robbins LLP Encourages CORT Stockholders to Contact the Firm for Information About Their Rights

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Corcept Therapeutics Incorporated (NASDAQ: CORT) common stock between October 31, 2024 and December 30, 2025. Corcept is a pharmaceutical company focused on the development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol.For more information, submit a...

uniQure N.V. Class Action Reminder – Robbins LLP Encourages QURE Stockholders to Contact the Firm for Information About Their Rights

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired uniQure N.V. (NASDAQ: QURE) ordinary shares between September 24, 2025 and October 31, 2025. uniQure is a biotechnology company developing gene therapies for rare diseases.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.What is the class period? September 24, 2025 – October 31, 2025What...
Back to Newsroom